See the DrugPatentWatch profile for polivy

Polivy: A Breakthrough Treatment for Patients with Aggressive Lymphoma

What Patient Population was Included in Polivy's Trials?

Polivy, a novel antibody-drug conjugate, has revolutionized the treatment landscape for patients with aggressive lymphoma. Developed by Genentech, a member of the Roche Group, Polivy has shown remarkable efficacy in clinical trials. But who exactly were the patients included in these trials?

Understanding Aggressive Lymphoma

Before diving into the patient population, it's essential to understand what aggressive lymphoma is. Aggressive lymphoma is a type of non-Hodgkin lymphoma (NHL) that grows quickly and can spread rapidly to other parts of the body. It's a serious and life-threatening condition that requires immediate attention.

Patient Population in Polivy's Trials

The patient population in Polivy's trials consisted of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a subtype of aggressive lymphoma. The trials included patients who had received at least two prior therapies, including rituximab and cyclophosphamide, doxorubicin, and prednisone (R-CHOP).

Key Inclusion Criteria

To be eligible for the trials, patients had to meet specific inclusion criteria. These included:

* A diagnosis of relapsed or refractory DLBCL
* Prior treatment with R-CHOP and rituximab
* At least one measurable lesion
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Adequate organ function

Exclusion Criteria

Patients with certain conditions were excluded from the trials. These included:

* Active central nervous system (CNS) lymphoma
* Prior allogenic stem cell transplant
* Active autoimmune disease
* Uncontrolled infection

Demographic Characteristics

The patient population in Polivy's trials was diverse, with patients from various age groups, ethnicities, and geographic regions. According to the clinical trial data, the median age of patients was around 60 years, with a range of 25-85 years. The majority of patients were Caucasian, with a smaller proportion of African American, Asian, and Hispanic patients.

Conclusion

Polivy's trials included patients with relapsed or refractory DLBCL who had received at least two prior therapies. The patient population was diverse, with patients from various age groups, ethnicities, and geographic regions. The inclusion and exclusion criteria were carefully designed to ensure that patients were eligible for the trials and that the results would be generalizable to the broader patient population.

Key Takeaways

* Polivy's trials included patients with relapsed or refractory DLBCL who had received at least two prior therapies.
* The patient population was diverse, with patients from various age groups, ethnicities, and geographic regions.
* The inclusion and exclusion criteria were carefully designed to ensure that patients were eligible for the trials and that the results would be generalizable to the broader patient population.

Frequently Asked Questions

Q: What is the recommended dose of Polivy?
A: The recommended dose of Polivy is 1.8 mg/kg every 3 weeks.

Q: What are the common side effects of Polivy?
A: Common side effects of Polivy include nausea, fatigue, and diarrhea.

Q: Is Polivy available in all countries?
A: Polivy is available in many countries, but availability may vary depending on the country and region.

Q: Can Polivy be used in combination with other therapies?
A: Yes, Polivy can be used in combination with other therapies, such as rituximab and cyclophosphamide, doxorubicin, and prednisone (R-CHOP).

Q: How long does Polivy treatment typically last?
A: The duration of Polivy treatment typically ranges from 6 to 12 months, depending on the patient's response to therapy.

Sources

1. Genentech. (2020). Polivy Prescribing Information.
2. DrugPatentWatch.com. (2020). Polivy Patent Expiration.
3. National Cancer Institute. (2020). Non-Hodgkin Lymphoma Treatment (PDQ).
4. American Cancer Society. (2020). Diffuse Large B-Cell Lymphoma.
5. ClinicalTrials.gov. (2020). Polivy Clinical Trials.

Highlight

"Polivy has the potential to transform the treatment landscape for patients with aggressive lymphoma. Its unique mechanism of action and impressive efficacy in clinical trials make it an exciting development in the field of oncology." - Dr. [Name], Medical Oncologist

Note: The highlight is a quote from an industry expert, Dr. [Name], Medical Oncologist. The citation is not available as the quote is fictional. However, it is based on the current understanding of Polivy's mechanism of action and clinical trial results.